Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05944692 · ClinicalTrials.gov registry record
Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)
A clinical trial of Epilepsy, sponsored by CREmedical.
- Recruiting
- Registry status
- 90
- Enrollment target
- 2
- Study locations
NCT05944692: Recruiting study of Epilepsy, sponsored by CREmedical.
NCT05944692 is a study of Epilepsy that is actively recruiting participants, run by CREmedical. The registered enrollment target is 90 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05944692, a study of Epilepsy, is actively recruiting participants, sponsored by CREmedical.
- RECRUITING
- Registry status
- 90 participants
- Enrollment target
- 2
- Study locations
Study Summary
Concurrent electroencephalography (EEG) and new tripolar EEG (tEEG) will be recorded from adult and pediatric patients. In some patients stereo EEG (sEEG) will also be recorded concurrently.
Primary Outcome
1. Establish the technical accuracy of tEEG (ability to record waveforms accurately and reproducibly in clinical conditions in comparison to conventional EEG). 2. Establish the diagnostic accuracy of tEEG compared to conventional EEG (combination of improved artifact reduction, better interrater agreement for interictal epileptiform activity, and earlier identification of ictal patterns), as determined by blinded expert EEG readers.
Conditions Studied
Interventions
- DEVICE Tripolar electroencephalography
Study Locations (2)
Arizona
- Barrow Neurological Institute Dignity Health dba St. Joseph's Hospital and Medical Center - Phoenix
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2026-08-03 |
What NCT05944692 shows while recruiting
NCT05944692 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Tripolar electroencephalography is the first listed.
NCT05944692 reports a single indexed study location in Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05944692 about?
NCT05944692 is a clinical study titled "Epilepsy Seizure Detection With Innovative Tripolar EEG (tEEG)". Concurrent electroencephalography (EEG) and new tripolar EEG (tEEG) will be recorded from adult and pediatric patients. In some patients stereo EEG (sEEG) will also be recorded concurrently.
What is the current status of trial NCT05944692?
This trial is currently recruiting. The enrollment target is 90 participants. The study started on 2025-09-01. Estimated completion is 2026-08-03.
What conditions does trial NCT05944692 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT05944692?
The interventions under investigation include: Tripolar electroencephalography (DEVICE).
Who is sponsoring clinical trial NCT05944692?
This trial is sponsored by CREmedical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05944692 being conducted?
This trial has 2 study locations across Arizona, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05944692's enrollment target sits among peer trials
90 61st of 160 higher than 99 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
RECRUITING
-
SeizEAR Safety Study
RECRUITING · NA
-
Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding
RECRUITING
-
Tumor Related Epilepsy
RECRUITING
-
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI